首页 > 市场调查报告书 > 製药

药物开发开发业务受託机关

市场调查报告书

商品编码

1469845

全球小分子创新者 API CDMO 市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Small Molecule Innovator API CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 172 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球小分子创新 API CDMO 市场需求预计将从 2023 年的 301.6 亿美元达到 2032 年近 573.9 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 7.41%。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对小分子创新药物 api cdmo 全球市场的各个细分市场进行了包容性评估。小分子创新者 api cdmo 产业的成长和趋势为本研究提供了整体方法。

市场区隔

小分子创新者 api cdmo 市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助战略家确定相应产品或服务的目标人群以及即将到来的机会。

按阶段类型

临床前
临床（一期、二期、三期）
商业的

依客户类型

製药（小型、中型、大型）
生物技术（小型、中型、大型）

按治疗领域

心血管疾病
肿瘤学
呼吸系统疾病
神经病学
代谢紊乱
传染性疾病
其他的

区域分析

本节涵盖区域展望，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲小分子创新 API CDMO 市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。小分子创新 API CDMO 市场的主要参与者包括 Lonza Group Ltd.、Novo Holdings (Catalent Inc.)、Thermo Fisher Scientific, Inc.、Siegfried Holding AG、Recipharm AB、CordenPharma International、Samsung Biologics、LabCorp、Ajinomoto Bio-医药服务、Piramal Pharma Solutions、Jubilant Life Sciences (Jubilant Biosys Ltd.)、药明康德股份有限公司。概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：小分子创新 API CDMO 公司的竞争格局

小分子创新者 API CDMO 市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
Lonza Group Ltd.

公司简介
公司收入
产品
最近的发展

Novo Holdings (Catalent Inc.)

公司简介
公司收入
产品
最近的发展

Thermo Fisher Scientific Inc.

公司简介
公司收入
产品
最近的发展

Siegfried Holding AG

公司简介
公司收入
产品
最近的发展

Recipharm AB

公司简介
公司收入
产品
最近的发展

CordenPharma International

公司简介
公司收入
产品
最近的发展

Samsung Biologics

公司简介
公司收入
产品
最近的发展

LabCorp

公司简介
公司收入
产品
最近的发展

Ajinomoto Bio-Pharma Services

公司简介
公司收入
产品
最近的发展

Piramal Pharma Solutions

公司简介
公司收入
产品
最近的发展

Jubilant Life Sciences (Jubilant Biosys Ltd.)

公司简介
公司收入
产品
最近的发展

WuXi AppTec Co. Ltd.

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114302

The global demand for Small Molecule Innovator API CDMO Market is presumed to reach the market size of nearly USD 57.39 Billion by 2032 from USD 30.16 Billion in 2023 with a CAGR of 7.41% under the study period 2024 - 2032.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of small molecule innovator api cdmo. The growth and trends of small molecule innovator api cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the small molecule innovator api cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Stage Type

Preclinical
Clinical (Phase I, Phase II, Phase III)
Commercial

By Customer Type

Pharmaceutical (Small, Medium, Large)
Biotechnology (Small, Medium, Large)

By Therapeutic Area

Cardiovascular Diseases
Oncology
Respiratory Disorders
Neurology
Metabolic Disorders
Infectious Diseases
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Small Molecule Innovator API CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Small Molecule Innovator API CDMO market include Lonza Group Ltd., Novo Holdings (Catalent Inc.), Thermo Fisher Scientific, Inc., Siegfried Holding AG, Recipharm AB, CordenPharma International, Samsung Biologics, LabCorp, Ajinomoto Bio-Pharma Services, Piramal Pharma Solutions, Jubilant Life Sciences (Jubilant Biosys Ltd.), WuXi AppTec Co., Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. SMALL MOLECULE INNOVATOR API CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Stage Type
- 3.7.2 Market Attractiveness Analysis By Customer Type
- 3.7.3 Market Attractiveness Analysis By Therapeutic Area
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY STAGE TYPE

5.1. Overview By Stage Type
5.2. Historical and Forecast Data
5.3. Analysis By Stage Type
5.4. Preclinical Historic and Forecast Sales By Regions
5.5. Clinical (Phase I, Phase II, Phase III) Historic and Forecast Sales By Regions
5.6. Commercial Historic and Forecast Sales By Regions

6. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY CUSTOMER TYPE

6.1. Overview By Customer Type
6.2. Historical and Forecast Data
6.3. Analysis By Customer Type
6.4. Pharmaceutical (Small, Medium, Large) Historic and Forecast Sales By Regions
6.5. Biotechnology (Small, Medium, Large) Historic and Forecast Sales By Regions

7. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY THERAPEUTIC AREA

7.1. Overview By Therapeutic Area
7.2. Historical and Forecast Data
7.3. Analysis By Therapeutic Area
7.4. Cardiovascular Diseases Historic and Forecast Sales By Regions
7.5. Oncology Historic and Forecast Sales By Regions
7.6. Respiratory Disorders Historic and Forecast Sales By Regions
7.7. Neurology Historic and Forecast Sales By Regions
7.8. Metabolic Disorders Historic and Forecast Sales By Regions
7.9. Infectious Diseases Historic and Forecast Sales By Regions
7.10. Others Historic and Forecast Sales By Regions

8. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE SMALL MOLECULE INNOVATOR API CDMO COMPANIES

9.1. Small Molecule Innovator API CDMO Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF SMALL MOLECULE INNOVATOR API CDMO INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Lonza Group Ltd.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Novo Holdings (Catalent Inc.)
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Siegfried Holding AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Recipharm AB
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. CordenPharma International
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Samsung Biologics
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. LabCorp
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Ajinomoto Bio-Pharma Services
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Piramal Pharma Solutions
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Jubilant Life Sciences (Jubilant Biosys Ltd.)
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. WuXi AppTec Co. Ltd.
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments